The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

Inflammation Research

Volumn 59, Issue 5, 2010, Pages 391-398

  Horak, Friedrich ^a   Zieglmayer, Petra ^b   Zieglmayer, Rene ^b   Lemell, Patrick ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Allergy Centre Vienna West   (Austria)

Author keywords

Allergic rhinitis; Bilastine; Cetirizine; Fexofenadine; Vienna Challenge Chamber

Indexed keywords

ANTIHISTAMINIC AGENT; BILASTINE; CETIRIZINE; FEXOFENADINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; GRASS POLLEN; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE OBSTRUCTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SNEEZING; TACHYCARDIA; VERTIGO; VIENNA CHALLENGE CHAMBER; VOLUNTEER;

ADOLESCENT; ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CETIRIZINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EYE DISEASES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MIDDLE AGED; NASAL MUCOSA; NOSE DISEASES; OPHTHALMIC SOLUTIONS; PIPERIDINES; PLACEBOS; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE;

EID: 77952604669     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-009-0117-4     Document Type: Article

References (30)

1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update [in collaboration with the World Health Organization, GA(2)LEN and AllerGen]. Allergy. 2008;63(Suppl 86):8-160.
3. Blaiss MS. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc. 2003;24:231-238
4. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005;60:788-794
5. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489-498
6. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111:S835-42.
7. Meltzer EO, Grant JA. Impact of cetirizine on the burden of allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83(5):455-463
8. Markham A, Wagstaff AJ. Fexofenadine. Drugs. 1998; 55:269-274
9. Corcostegui R, Labeaga L, Innerarity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihis-taminic activity. Drugs R D. 2005;6:371-384
10. Sologuren A, Valiente R. Relationship of dose to inhibition of wheal and flare for 5 doses bilastine and 10 mg cetirizine. In: Proceedings of the 36th ACCP Annual Meeting, San Francisco, CA, 9-11 September; 2007.
11. Audicana MT. A double blind, randomized, dose ranging trial in four parallel groups of 10, 20 and 30 mg bilastine once daily vs placebo in the symptomatic treatment of chronic idiopatic urticaria. In: Proceedings of SEIAC, Santander (Spain); 2007.
12. Alison M, Benoit T, Sologuren A. Lack of significant effect of bilastine on ventricular repolarization. A throrough QT/QTc study. In: Proceedings of the EAACI Congress, Barcelona (Spain), 7-11 June; 2008.
13. Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psycho-pharmacol. 2008;28:675-685
14. Gonzalo A, Lucero ML, Orjales A. Early identification of the processes involved in bilastine bioavailability in rats. In: Proceedings of 10th European Regional ISSX Meeting, Vienna, Austria, 18-21 May; 2008.
15. Horak F, Jäger S. Wiener Provokations-Kammer (Vienna Challenge Chamber): eine neue Methode des Allergenexpositionstests. Wiener klin Wochenschr. 1987;99:509-510
16. Horak F, Stübner UP, Zieglmayer R, Kavina A, De Vos C, Burtin B, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol. 2001;125:73-79
17. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60:24-31.
18. Stuebner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit\the Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004;20:891-902.
19. Stuebner P, Horak F, Zieglmayer R, Arnaiz E, Leuratti C, Perez I, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2006;96:37-44.
20. Canonica GW, Bousquet J, Van HG, Bachert C, Durham SR, Klimek L, et al. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med. 2006;100:1706-1715
21. Horak F, Stübner UP, Zieglmayer R, Harris AG. Effect of desl-oratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109:956-961
22. Horak F, Stübner UP. Decongestant activity of desloratadine in controlled-allergen-exposure trials. Clin Drug Invest. 2002; 22(Suppl 2):13-20.
23. Horak F, Stübner UP, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003;58:481-485
24. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Correlation of nasal inflammation and nasal airflow with forced expiratory volume in 1 second in patients with perennial allergic rhinitis and asthma. Ann Allergy Asthma Immunol. 2004;93:575-580
25. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004;34:958-964
26. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005; 5(13-14):1800-1808
27. Oswald S, Grube M, Siegmund W, Kroemer HK. Transporter-mediated uptake into cellular compartments. Xenobiotica. 2007;37(10-11):1171-1195
28. Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos. 2005;33:963-968
29. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, et al. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008;73:1474-1483
30. Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, et al. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos. 2008;36:61-64